The Extracorporeal Membrane Oxygenation Machine Market have evolved as a ground breaking tool in critical care in the ever-evolving world of medical technology. Patients with severe lung or heart failure can receive temporary respiratory and/or cardiac support from these life-supporting devices. The patient’s organs can rest and recuperate while their blood is oxygenated and carbon dioxide is removed by the ECMO system, which serves as an external lung or heart. Technology improvements, greater awareness, and an increase in respiratory and cardiac conditions are all driving the amazing rise of the global market for ECMO devices.
Neonatals, children, and adults are now all using ECMO machines, which were first utilised largely in paediatric situations. They are now also used for ECMO-assisted organ transplant procedures, the treatment of acute respiratory distress syndrome (ARDS), COVID-19-related respiratory failure, and the management of trauma-induced lung damage, in addition to cardiac and respiratory support.
Get Your Copy Today: Uncover the Massive Market Potential of Extracorporeal Membrane Oxygenation Machine Market – Download Our Sample Report Now @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14300
Extracorporeal membrane oxygenation machine sales were estimated at US$ 531 million in 2021. From 2022 to 2032, the market is projected to grow steadily at a CAGR of 5%, reaching US$ 908 billion by the end of that year.
The market for ECMO machines has shown tremendous growth in recent years and is anticipated to keep growing quickly. The frequency of respiratory and cardiac disorders, the ageing of the population, and the increased need for sophisticated life-support systems are all factors that are fueling this expansion. Additionally, it is anticipated that ongoing research and development activities in ECMO technology would further improve its capabilities and stimulate market growth.
Key Takeaways:
- By application, high demand for early diagnosis and diagnostic imaging, and technological advancements in the extracorporeal membrane oxygenation machine market are expected to propel the respiratory segment to the top.
- The arterio-venous segment is likely to hold the majority of the market based on modality owing to the benefits associated with this technology segment, such as effective dynamic range, thereby boosting the ECMO systems market growth.
- Based on patient type, the adult segment is projected to lead the market as the global burden of cardiac and respiratory diseases in adults is rising due to increased consumption of alcohol, tobacco, smoking, and a sedentary lifestyle.
Feel free to reach out to our analyst for any queries you might have @ https://www.futuremarketinsights.com/ask-question/rep-gb-14300
Because of the presence of major players and the rising number of product launches, government support for high-quality healthcare, which is also seen as one of the key trends in the ECMO systems market, and the rising prevalence of diseases in the United States and Canada, such as chronic obstructive pulmonary disease, which increases hospital admission and is favoured by reimbursement policies, the North American market is anticipated to lead the ECMO systems market. an FMI analyst claims.
Competitive Landscape:
- Medtronic plc (USA),
- Fresenius Medical Care A.G. & Co. KGAA (Germany),
- Getinge Group (Sweden),
- Microport (China),
- Origin Biomedical (USA),
- Terumo Cardiovascular Systems Corporation,
- Livanova plc (United Kingdom),
- Nipro Corporation (Japan),
- Euro sets S.R.L. (Italy),
- Cytosorbents Corporation (Australia),
- Abiomed
Major global players produce the majority of ECMO support systems. Market leaders have established their position by investing more in research and having a better distribution system.
To stay competitive in the market, extracorporeal membrane oxygenation machines manufacturers are actively involved in product launches and technological innovation.
- ALung Technologies, Inc. has begun commercialization of its ground-breaking next-generation artificial lung. The device is based on University of Pittsburgh intellectual property licensed to ALung Technologies, Inc.
- Medtronic has released its artificial lung therapy for the treatment of COVID-19. An artificial pump that pumps blood from a person’s body to an oxygenator is called ECMO, and it also has an FDA-approved device for ECMO procedures lasting up to 6 hours.
Customize Your Knowledge: Unlock Targeted Insights to Drive Growth in the Extracorporeal Membrane Oxygenation Machine Market @ https://www.futuremarketinsights.com/customization-available/rep-gb-14300
Key Segments By Product:
- ECMO Machines
- Portable Devices
- Static Devices
- Software
By Service Type:
- Application
- Middleware
- Infrastructure
By Component:
- Pumps
- Oxygenators
- Controllers
- Cannul
- Assessories
By Modality:
- Veno-Venous
- Veno-Arterials
- Arterio-Venous
Get Ahead with Detailed Market Intelligence: Purchase Now to Access @ https://www.futuremarketinsights.com/checkout/14300
By Patient Type:
- Neonates
- Pediatrics
- Adults
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
